← Back to Search

Other

Albuvirtide for HIV (ABL Trial)

Phase 2
Waitlist Available
Research Sponsored by Frontier Biotechnologies Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 16 weeks in part 1 and part 2, 28 weeks in part 3
Awards & highlights

ABL Trial Summary

This trial is testing a new long-acting HIV treatment that could help people stay virally suppressed.

Eligible Conditions
  • HIV

ABL Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~16 weeks in part 1 and part 2, 28 weeks in part 3
This trial's timeline: 3 weeks for screening, Varies for treatment, and 16 weeks in part 1 and part 2, 28 weeks in part 3 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Proportion of participants with HIV-1 RNA < 50 copies/mL at the end of treatment phase in Part 3 of the study.
Secondary outcome measures
Emergence of new resistance mutations to antiretroviral drugs as evaluated by GenoSure Archive or PhenoSense GT Assay
Mean change in CD4 cell count, at each visit within the treatment phase
Mean change in CD4:CD8 ratio, at each visit within the treatment phase
+7 more

ABL Trial Design

7Treatment groups
Experimental Treatment
Active Control
Group I: Optimal Dose: albuvirtide & 3BNC117Experimental Treatment2 Interventions
albuvirtide and 3BNC117 every 2 or 4 weeks
Group II: Cohort 4: albuvirtide & 3BNC117Experimental Treatment2 Interventions
albuvirtide 0.16 g and 3BNC117 0.8 g every 4 weeks
Group III: Cohort 3: albuvirtide & 3BNC117Experimental Treatment2 Interventions
albuvirtide 0.32 g and 3BNC117 0.8 g every 4 weeks
Group IV: Cohort 2: albuvirtide & 3BNC117Experimental Treatment2 Interventions
albuvirtide 0.32 g and 3BNC117 2 g every 4 weeks
Group V: Cohort 1: albuvirtide & 3BNC117Experimental Treatment2 Interventions
albuvirtide 0.32 g and 3BNC117 2 g every 2 weeks
Group VI: Control Arm 1: Baseline ARTActive Control1 Intervention
Subjects continuing on baseline ART
Group VII: Control Arm 2: Baseline ARTActive Control1 Intervention
Subjects continuing on baseline ART
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Albuvirtide
Not yet FDA approved
3BNC117
2017
Completed Phase 2
~170

Find a Location

Who is running the clinical trial?

Frontier Biotechnologies Inc.Lead Sponsor
12 Previous Clinical Trials
3,416 Total Patients Enrolled
Frontier clinical teamStudy DirectorFrontier Biotechnologies Inc.
1 Previous Clinical Trials
34 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects
2018. "Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03719664.
~13 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top